Preprint / Version 1

Gene therapy and gene editing in human disease: CRISPR and beyond

##article.authors##

  • Sarah Sabin n/a

DOI:

https://doi.org/10.58445/rars.484

Keywords:

Gene Therapy, Gene Editing, CRISPR

Abstract

Exploring genetic diseases and disorders and new technologies in gene therapy and gene editing treating these disorders. 

References

Giorgio Ottaviano et al. Phase 1 clinical trial of CRISPR-engineered CAR19 universal T cells for treatment of children with refractory B cell leukemia.Sci. Transl. Med.14,eabq3010(2022).DOI:10.1126/scitranslmed.abq3010

Health Direct staff. (2021, September). Williams Syndrome. Health Direct. Retrieved September 18, 2023, from https://www.healthdirect.gov.au/williams-syndrome

Montaño, A., Forero-Castro, M., Hernández-Rivas, J. M., García-Tuñón, I., & Benito, R. (2018). Targeted genome editing in acute lymphoblastic leukemia: a review. BMC biotechnology, 18(1), 45. https://doi.org/10.1186/s12896-018-0455-9

Morris, C. (2023, April 13). Williams Syndrome. National Library of Medicine. Retrieved September 18, 2023, from https://www.ncbi.nlm.nih.gov/books/NBK1249/

Vajen, B., Ronez, J., Rathje, W., Heinisch, L., Ebeling, S., Gebhard, U., Hößle, C., & Schlegelberger, B. (2021). Students' attitudes towards somatic genome editing versus genome editing of the germline using an example of familial leukemia. Journal of community genetics, 12(3), 397–406. https://doi.org/10.1007/s12687-021-00528-1

Downloads

Posted

2023-09-23

Categories

License

Copyright (c) 2023 Sarah Sabin

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

You are free to:

  1. Share — copy and redistribute the material in any medium or format for any purpose, even commercially.
  2. Adapt — remix, transform, and build upon the material for any purpose, even commercially.
  3. The licensor cannot revoke these freedoms as long as you follow the license terms.

Under the following terms:

  1. Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
  2. No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license